Philippe De WalsM.D., Ph.D.

Gagneur A, Battista MC, Boucher FD, Tapiero B, Quach C, De Wals P, Lemaitre T, Farrands A, Boulianne N, Sauvageau C, Ouakki M, Gosselin V, Petit G, Jacques MC, Dube E

Promoting vaccination in maternity wards horizontal line motivational interview technique reduces hesitancy and enhances intention to vaccinate, results from a multicentre non-controlled pre- and post-intervention RCT-nested study, Quebec, March 2014 to February 2015.

Euro Surveill, 24 (36), 2019, ISSN: 1025-496X.

Résumé | Liens:

Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, Benard E, Brisson M

Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.

CMAJ, 191 (34), p. E932-E939, 2019, ISSN: 0820-3946.

Résumé | Liens:

Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P

Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch.

Vaccine, 37 (31), p. 4243-4245, 2019, ISSN: 0264-410X.

Résumé | Liens:

De Wals P, Espinoza-Moya ME, Beland D

Kingdon's Multiple Streams Framework and the Analysis of Decision-Making Processes Regarding Publicly-Funded Immunization Programs.

Expert Rev Vaccines, 18 (6), p. 575-585, 2019, ISSN: 1476-0584.

Résumé | Liens:

Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya JA, Jodar L

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies.

Clin Infect Dis, 68 (12), p. 2135-2143, 2019, ISSN: 1058-4838.

Résumé | Liens:

Marten O, Koerber F, Bloom D, Bullinger M, Buysse C, Christensen H, De Wals P, Dohna-Schwake C, Henneke P, Kirchner M, Knuf M, Lawrenz B, Monteiro AL, Sevilla JP, Van de Velde N, Welte R, Wright C, Greiner W

A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.

Health Qual Life Outcomes, 17 (1), p. 87, 2019.

Résumé | Liens:

Gagneur A, Quach C, Boucher FD, Tapiero B, De Wals P, Farrands A, Lemaitre T, Boulianne N, Sauvageau C, Ouakki M, Gosselin V, Gagnon D, Petit G, Jacques MC, Dube E

Promoting vaccination in the province of Québec: the PromoVaQ randomized controlled trial protocol.

BMC Public Health, 19 (1), p. 160, 2019.

Résumé | Liens:

LeMeur JB, Lefebvre B, Proulx JF, De Wals P

Limited impact of pneumococcal vaccines on invasive pneumococcal disease in Nunavik (Quebec).

Can J Public Health, 110 (1), p. 36-43, 2019, ISSN: 0008-4263.

Résumé | Liens:

Dube E, Farrands A, Lemaitre T, Boulianne N, Sauvageau C, Boucher FD, Tapiero B, Quach C, Ouakki M, Gosselin V, Gagnon D, De Wals P, Petit G, Jacques MC, Gagneur A

Overview of knowledge, attitudes, beliefs, vaccine hesitancy and vaccine acceptance among mothers of infants in Quebec, Canada.

Hum Vaccin Immunother, 15 (1), p. 113-120, 2019.

Résumé | Liens:

Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, Echaniz-Aviles G, Hakawi A, Kamiya H, Karachaliou A, Lucidarme J, Meiring S, Mironov K, Safadi MAP, Shao Z, Smith V, Steffen R, Stenmark B, Taha MK, Trotter C, Vazquez JA, Zhu B

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations.

Expert Rev Vaccines, 18 (1), p. 15-30, 2019, ISSN: 1476-0584.

Résumé | Liens: